Yahoo India Web Search

Search results

    • FDA clears Artelo’s FABP5 inhibitor trial

      FDA clears Artelo’s FABP5 inhibitor trial

      Clinical Trials Arena· 6 hours ago

      ART26.12, Artelo’s lead asset, is the first selective FABP5 inhibitor to enter clinical trials, according to the US-based company. The Phase I single...